SG11202012415PA - Bicyclic peptide ligands specific for nectin-4 - Google Patents
Bicyclic peptide ligands specific for nectin-4Info
- Publication number
- SG11202012415PA SG11202012415PA SG11202012415PA SG11202012415PA SG11202012415PA SG 11202012415P A SG11202012415P A SG 11202012415PA SG 11202012415P A SG11202012415P A SG 11202012415PA SG 11202012415P A SG11202012415P A SG 11202012415PA SG 11202012415P A SG11202012415P A SG 11202012415PA
- Authority
- SG
- Singapore
- Prior art keywords
- nectin
- peptide ligands
- ligands specific
- bicyclic peptide
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1810250.9A GB201810250D0 (en) | 2018-06-22 | 2018-06-22 | Bicycle peptide ligands specific for nectin-4 |
| GBGB1815684.4A GB201815684D0 (en) | 2018-09-26 | 2018-09-26 | Bicyclic peptide ligands specific for nectin-4 |
| GBGB1818499.4A GB201818499D0 (en) | 2018-11-13 | 2018-11-13 | Bicyclic peptide ligands specific for nectin-4 |
| GBGB1904632.5A GB201904632D0 (en) | 2019-04-02 | 2019-04-02 | Bicyclic peptide ligands specific for nectin-4 |
| PCT/GB2019/051741 WO2019243833A1 (en) | 2018-06-22 | 2019-06-21 | Bicyclic peptide ligands specific for nectin-4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012415PA true SG11202012415PA (en) | 2021-01-28 |
Family
ID=67106071
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012413TA SG11202012413TA (en) | 2018-06-22 | 2019-06-21 | Bicyclic peptide ligands specific for nectin-4 |
| SG11202012415PA SG11202012415PA (en) | 2018-06-22 | 2019-06-21 | Bicyclic peptide ligands specific for nectin-4 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012413TA SG11202012413TA (en) | 2018-06-22 | 2019-06-21 | Bicyclic peptide ligands specific for nectin-4 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11180531B2 (en) |
| EP (2) | EP3810167A1 (en) |
| JP (4) | JP2021527701A (en) |
| KR (2) | KR20210025603A (en) |
| CN (2) | CN112601539A (en) |
| AU (2) | AU2019289199A1 (en) |
| BR (2) | BR112020025715A2 (en) |
| CA (2) | CA3101164A1 (en) |
| IL (2) | IL279488A (en) |
| MX (2) | MX2020013784A (en) |
| PH (1) | PH12020552179A1 (en) |
| SG (2) | SG11202012413TA (en) |
| WO (2) | WO2019243832A1 (en) |
| ZA (1) | ZA202100442B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032678A (en) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | Bicyclic peptide ligands with detectable moieties and uses thereof |
| CN118772242A (en) | 2017-08-04 | 2024-10-15 | 拜斯科技术开发有限公司 | CD137 specific bicyclic peptide ligands |
| TWI825046B (en) * | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| EP3965827A1 (en) | 2019-05-09 | 2022-03-16 | BicycleTX Limited | Bicyclic peptide ligands specific for ox40 |
| TW202110485A (en) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | Heterotandem bicyclic peptide complex |
| US11508566B2 (en) * | 2019-09-03 | 2022-11-22 | National Taiwan University | Use of anthranilic acid derivative as matrix for MALDI mass spectrometry |
| WO2021064428A1 (en) | 2019-10-03 | 2021-04-08 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| GB201914872D0 (en) * | 2019-10-15 | 2019-11-27 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
| CA3173253A1 (en) * | 2020-02-28 | 2021-09-02 | Ascend Biopharmaceuticals Ltd | Methods of treatment and related compositions |
| CN115697417A (en) * | 2020-05-20 | 2023-02-03 | 拜斯科技术开发有限公司 | NECTN-4 specific bicyclic peptide ligands and uses thereof |
| KR20230074721A (en) | 2020-08-17 | 2023-05-31 | 바이사이클티엑스 리미티드 | NECTIN-4 Specific Bicyclic Conjugates and Uses Thereof |
| EP4213844A1 (en) * | 2020-09-17 | 2023-07-26 | Mirati Therapeutics, Inc. | Combination therapies |
| GB202016331D0 (en) * | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
| MX2023008168A (en) | 2021-01-08 | 2023-07-25 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes. |
| US20240325554A1 (en) | 2021-01-11 | 2024-10-03 | Bicycle TX Limited | Methods for treating cancer |
| BR112023022549A2 (en) * | 2021-04-30 | 2024-01-02 | Jiangsu Mabwell Health Pharmaceutical R&D Co Ltd | ANTIBODY-DRUG CONJUGATE TARGETED TO NECTIN-4 AND METHOD OF PREPARATION THEREOF AND USE THEREOF |
| WO2022253051A1 (en) * | 2021-06-01 | 2022-12-08 | 南京明德新药研发有限公司 | Polypeptide conjugated drug and use thereof |
| CA3229976A1 (en) | 2021-09-03 | 2023-03-09 | Bicycletx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| WO2023051396A1 (en) * | 2021-09-29 | 2023-04-06 | 南京明德新药研发有限公司 | Tricyclic polypeptide conjugated drug and use thereof |
| GB202114279D0 (en) * | 2021-10-06 | 2021-11-17 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
| CN118201627A (en) * | 2021-10-19 | 2024-06-14 | 西藏海思科制药有限公司 | Nectin-4 bicyclic peptide ligands and uses thereof |
| CN114133434B (en) * | 2021-12-01 | 2022-11-15 | 北京大学第一医院 | Nectin-4 targeted bicyclic peptide nuclide ligand and probe |
| CN116768978A (en) * | 2022-03-11 | 2023-09-19 | 上海智肽生物科技有限公司 | Nectin-4 targeting peptide compounds and drug conjugates thereof |
| CN115400141B (en) * | 2022-09-20 | 2023-08-11 | 天津医科大学总医院 | Application of STING agonist in preparation of medicine for treating chronic pruritus |
| WO2024184661A1 (en) | 2023-03-09 | 2024-09-12 | Bicycletx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2642514A (en) | 1946-08-10 | 1953-06-16 | American Cyanamid Co | Ion exchange process with magnetic ion exchange resins |
| GB1239978A (en) | 1968-07-15 | 1971-07-21 | Permutt Company Ltd | Ion-exchange processes |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| DK0859841T3 (en) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein / (poly) peptide libraries |
| GB9819592D0 (en) | 1998-09-08 | 1998-11-04 | Smithkline Beecham Plc | Novel compounds |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| DE69938353T2 (en) | 1998-09-24 | 2009-03-05 | Indiana University Research and Technology Corp., Indianapolis | WATER-SOLUBLE LUMINESCENT QUANTUM-DOTS AND THEIR BIOKON JUGATE |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| EA006227B1 (en) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | PIRROLO(2,3-d)PYRIMIDINE COMPOUNDS |
| PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
| DK1389617T3 (en) | 2001-04-27 | 2007-05-07 | Zenyaku Kogyo Kk | Heterocyclic compound and anti-tumor agent containing it as the active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| DK1487972T3 (en) | 2002-02-21 | 2015-10-19 | Inst Virology | MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use. |
| CA2495072A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| JP2006523237A (en) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | PI-3 kinase inhibitor prodrug |
| KR101168441B1 (en) | 2003-05-30 | 2012-07-25 | 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| ES2541489T3 (en) | 2004-02-06 | 2015-07-21 | Morphosys Ag | Human anti-CD38 antibodies and uses for them |
| CA2505655C (en) | 2004-04-28 | 2013-07-09 | Warren Chan | Stable, water-soluble quantum dot, method of preparation and conjugates thereof |
| AU2005245875C1 (en) | 2004-05-13 | 2017-08-31 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| ES2428869T3 (en) | 2005-01-24 | 2013-11-12 | Pepscan Systems B.V. | Binding compounds, immunogenic and peptidomimetic compounds |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| WO2007040650A2 (en) | 2005-05-12 | 2007-04-12 | Abbott Laboratories | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR101888321B1 (en) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| ES2513165T3 (en) | 2005-10-07 | 2014-10-24 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol-3-kinase inhibitors |
| BR122021011787B1 (en) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Biaryl metapyrimidine kinase inhibitors, pharmaceutical composition and process for preparing a pharmaceutical composition |
| UA116187C2 (en) | 2005-12-13 | 2018-02-26 | Інсайт Холдінгс Корпорейшн | HETERO aryl substituted pyrrolo [2,3-b] Pyridines and pyrrolo [2,3-b] Pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
| AR060631A1 (en) | 2006-04-26 | 2008-07-02 | Piramed Ltd | DERIVATIVES OF PIRIMIDINE AND ITS USE AS INHIBITORS OF PHOSFATIDYLNOSITOL 3-QUINASE (PI3K) |
| MX2009002775A (en) | 2006-09-15 | 2009-06-17 | Siemens Medical Solutions | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins. |
| EP2532235A1 (en) | 2006-09-22 | 2012-12-12 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| KR20150043565A (en) | 2007-03-12 | 2015-04-22 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | Phenyl amino pyrimidine compounds and uses thereof |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
| JP2010530437A (en) | 2007-06-18 | 2010-09-09 | メディミューン，エルエルシー | Synergistic treatment of cells expressing EphA2 and ErbB2 |
| JP5932217B2 (en) | 2007-07-12 | 2016-06-08 | ジーアイティーアール， インコーポレイテッド | Combination therapy using GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (en) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | IDO inhibitor |
| AU2008353145B2 (en) | 2008-01-03 | 2013-09-12 | Universite D' Aix-Marseille | Bitherapy and tritherapy used for treating an HIV-positive patient |
| PL2257624T3 (en) | 2008-02-05 | 2012-09-28 | Medical Res Council | Methods and compositions |
| PT2288610T (en) | 2008-03-11 | 2016-10-17 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| CN102245640B (en) | 2008-12-09 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| SG178991A1 (en) | 2009-09-03 | 2012-04-27 | Schering Corp | Anti-gitr antibodies |
| WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
| NZ599516A (en) | 2009-12-10 | 2013-11-29 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| EP2343081A1 (en) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| JP2013518807A (en) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | Multispecific peptide |
| MX345232B (en) | 2010-03-04 | 2017-01-20 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof. |
| CN102918060B (en) | 2010-03-05 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | Anti-human CSF-1R antibody and uses thereof |
| JP5989547B2 (en) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Antibody to human CSF-1R and use thereof |
| TR201900368T4 (en) | 2010-05-04 | 2019-02-21 | Five Prime Therapeutics Inc | Antibodies that bind to Csf1r. |
| NZ714128A (en) | 2010-09-09 | 2017-10-27 | Pfizer | 4-1bb binding molecules |
| ES2874306T3 (en) * | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugates of antibodies and drugs (CAF) that bind to 191P4D12 proteins |
| WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
| KR102243575B1 (en) | 2010-12-09 | 2021-04-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130072598A1 (en) | 2011-03-18 | 2013-03-21 | Board Of Regents Of The University Of Nebraska | Thermoplastics from Distillers Dried Grains and Feathers |
| NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
| EP2699264B1 (en) | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
| US9994617B2 (en) | 2011-10-07 | 2018-06-12 | Bicyclerd Limited | Modulation of structured polypeptide specificity |
| PT2785375T (en) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| EP2812355A4 (en) | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | Compositions and methods for using csf1r inhibitors |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| RU2670743C9 (en) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| WO2014036357A1 (en) | 2012-08-31 | 2014-03-06 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| PT2970487T (en) | 2013-03-12 | 2020-06-17 | Molecular Templates Inc | Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types |
| US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| WO2014190257A2 (en) | 2013-05-23 | 2014-11-27 | Ohio State Innovation Foundation | Chemical synthesis and screening of bicyclic peptide libraries |
| ES2715379T3 (en) | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novel Polypeptides |
| WO2015171938A1 (en) | 2014-05-08 | 2015-11-12 | Novodiax, Inc. | Direct immunohistochemistry assay |
| CN113861268A (en) | 2014-05-21 | 2021-12-31 | 恩特拉达治疗学股份有限公司 | Cell penetrating peptides and methods of making and using the same |
| GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
| DK3215518T3 (en) | 2014-10-29 | 2021-05-25 | Bicyclerd Ltd | BICYCLIC PEPTIDE LIGANDS SPECIFIC TO MT1-MMP |
| WO2016171242A1 (en) | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Detection of epha2 |
| JP2018521960A (en) * | 2015-04-28 | 2018-08-09 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） | Novel inhibitors of enzyme activated factor XII (FXIIa) |
| JP6985252B2 (en) * | 2015-09-09 | 2021-12-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Antibodies with specificity for Nectin-4 and their use |
| JP2019512477A (en) | 2016-03-16 | 2019-05-16 | メリマック ファーマシューティカルズ インコーポレーティッド | Nanoliposome targeting and related diagnostics of the ephrin receptor A2 (EPHA2) |
| MA45328A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
| EP3445788B1 (en) * | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018096365A1 (en) | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
| CN110603261A (en) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | Peptide derivatives having novel bond structure |
| MX2019007367A (en) | 2016-12-23 | 2020-01-27 | Bicycletx Ltd | Peptide ligands for binding to mt1-mmp. |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| BR112019017628A2 (en) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | cd137 x ta binding molecule, pharmaceutical compositions, use of cd137 x ta binding molecule, cd137 binding molecule, use of cd137 binding molecule, her2 / neu binding molecule, use of her2 binding molecule / neu, and use of a composition |
| GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| WO2018197893A1 (en) | 2017-04-27 | 2018-11-01 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| CN111032678A (en) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | Bicyclic peptide ligands with detectable moieties and uses thereof |
| CN118772242A (en) | 2017-08-04 | 2024-10-15 | 拜斯科技术开发有限公司 | CD137 specific bicyclic peptide ligands |
| EP3668550A1 (en) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| WO2019034866A1 (en) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (en) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
| WO2019136442A1 (en) | 2018-01-08 | 2019-07-11 | Kleo Pharmaceuticals, Inc. | Cd16a binding agents and uses thereof |
| BR112020014576A2 (en) | 2018-02-23 | 2020-12-08 | Bicycletx Limited | MULTIMERIC BICYCLIC PEPTIDE BINDERS |
| EP3774851A1 (en) * | 2018-04-04 | 2021-02-17 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
| WO2019226617A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| JP2022512779A (en) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | Bicyclic peptide ligands and their use |
| US20200129630A1 (en) | 2018-10-30 | 2020-04-30 | Bicyclerd Limited | Methods for treating cancer |
| KR20210123295A (en) | 2018-12-13 | 2021-10-13 | 바이사이클티엑스 리미티드 | Bicyclic peptide ligand specific for MT1-MMP |
| AU2019402097A1 (en) | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| CN113474045A (en) | 2018-12-21 | 2021-10-01 | 拜斯科技术开发有限公司 | PD-L1 specific bicyclic peptide ligands |
| US10882987B2 (en) | 2019-01-09 | 2021-01-05 | Nova Chemicals (International) S.A. | Ethylene interpolymer products having intermediate branching |
| WO2020178574A1 (en) | 2019-03-04 | 2020-09-10 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| EP3946462A1 (en) | 2019-04-02 | 2022-02-09 | BicycleTX Limited | Bicycle toxin conjugates and uses thereof |
| EP3965827A1 (en) | 2019-05-09 | 2022-03-16 | BicycleTX Limited | Bicyclic peptide ligands specific for ox40 |
| TW202108165A (en) | 2019-05-10 | 2021-03-01 | 英商拜西克爾德有限公司 | Methods for treating cancer |
| TW202110485A (en) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | Heterotandem bicyclic peptide complex |
| EP4013501A1 (en) | 2019-08-13 | 2022-06-22 | BicycleTX Limited | Modified multimeric bicyclic peptide ligands |
| WO2021064428A1 (en) | 2019-10-03 | 2021-04-08 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| GB201914872D0 (en) | 2019-10-15 | 2019-11-27 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
| EP4045075A1 (en) | 2019-10-16 | 2022-08-24 | Bicyclerd Limited | Methods for treating cancer |
| MX2022006001A (en) | 2019-11-27 | 2022-10-27 | Bicycletx Ltd | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF. |
| CN115697417A (en) | 2020-05-20 | 2023-02-03 | 拜斯科技术开发有限公司 | NECTN-4 specific bicyclic peptide ligands and uses thereof |
| IL298868A (en) | 2020-06-12 | 2023-02-01 | Bicycletx Ltd | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
| KR20230074721A (en) | 2020-08-17 | 2023-05-31 | 바이사이클티엑스 리미티드 | NECTIN-4 Specific Bicyclic Conjugates and Uses Thereof |
| MX2023008168A (en) | 2021-01-08 | 2023-07-25 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes. |
| US20240325554A1 (en) | 2021-01-11 | 2024-10-03 | Bicycle TX Limited | Methods for treating cancer |
| CA3229976A1 (en) | 2021-09-03 | 2023-03-09 | Bicycletx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| EP4433025A1 (en) | 2021-11-16 | 2024-09-25 | BicycleTx Limited | Methods for treating cancer |
-
2019
- 2019-06-20 US US16/446,901 patent/US11180531B2/en active Active
- 2019-06-21 MX MX2020013784A patent/MX2020013784A/en unknown
- 2019-06-21 CA CA3101164A patent/CA3101164A1/en active Pending
- 2019-06-21 US US17/252,038 patent/US20210269480A1/en active Pending
- 2019-06-21 KR KR1020217002143A patent/KR20210025603A/en unknown
- 2019-06-21 KR KR1020217002144A patent/KR20210029783A/en not_active Application Discontinuation
- 2019-06-21 AU AU2019289199A patent/AU2019289199A1/en active Pending
- 2019-06-21 SG SG11202012413TA patent/SG11202012413TA/en unknown
- 2019-06-21 JP JP2020571431A patent/JP2021527701A/en active Pending
- 2019-06-21 MX MX2021000195A patent/MX2021000195A/en unknown
- 2019-06-21 CN CN201980054817.8A patent/CN112601539A/en active Pending
- 2019-06-21 WO PCT/GB2019/051740 patent/WO2019243832A1/en unknown
- 2019-06-21 WO PCT/GB2019/051741 patent/WO2019243833A1/en unknown
- 2019-06-21 EP EP19734150.6A patent/EP3810167A1/en active Pending
- 2019-06-21 EP EP19739341.6A patent/EP3810169A1/en active Pending
- 2019-06-21 CN CN201980053964.3A patent/CN112566651A/en active Pending
- 2019-06-21 BR BR112020025715-0A patent/BR112020025715A2/en unknown
- 2019-06-21 BR BR112020025985-3A patent/BR112020025985A2/en unknown
- 2019-06-21 SG SG11202012415PA patent/SG11202012415PA/en unknown
- 2019-06-21 AU AU2019289200A patent/AU2019289200A1/en active Pending
- 2019-06-21 JP JP2020571434A patent/JP2021527702A/en active Pending
- 2019-06-21 CA CA3101427A patent/CA3101427A1/en active Pending
-
2020
- 2020-12-15 PH PH12020552179A patent/PH12020552179A1/en unknown
- 2020-12-16 IL IL279488A patent/IL279488A/en unknown
- 2020-12-16 IL IL279489A patent/IL279489A/en unknown
-
2021
- 2021-01-21 ZA ZA2021/00442A patent/ZA202100442B/en unknown
- 2021-09-30 US US17/491,078 patent/US11453702B2/en active Active
-
2022
- 2022-08-17 US US17/820,286 patent/US11912792B2/en active Active
-
2024
- 2024-02-05 JP JP2024015779A patent/JP2024062999A/en active Pending
- 2024-05-15 JP JP2024079396A patent/JP2024122976A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100442B (en) | Bicyclic peptide ligands specific for nectin-4 | |
| IL275437A (en) | Bicyclic peptide ligands specific for epha2 | |
| GB201721265D0 (en) | Bicyclic peptide ligands specific for EphA2 | |
| IL283873A (en) | Bicyclic peptide ligands specific for mt1-mmp | |
| GB201820316D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
| IL283874A (en) | Bicyclic peptide ligands specific for mt1-mmp | |
| GB201820325D0 (en) | Bicyclic peptide ligands specific for psma | |
| GB201820295D0 (en) | Bicyclic peptide ligands specific for MT1-MMP | |
| GB201820320D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| GB201818499D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201815684D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201918495D0 (en) | Bicyclic peptide ligands specific for il-46 | |
| GB201904632D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201720934D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| GB201820956D0 (en) | Bicyclic peptide ligands specific for pd-l1 | |
| GB201818603D0 (en) | Bicyclic peptide ligands specific for epha2 | |
| GB201820312D0 (en) | Bicyclic peptide ligands specific for IL-6 | |
| GB201712693D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201820314D0 (en) | Bicyclic peptide ligands specific for KLK7 | |
| GB201820324D0 (en) | Bicyclic peptide ligands specific for vegf | |
| GB201820318D0 (en) | Bicyclic peptide ligands specific for cathepsin G | |
| GB201820326D0 (en) | Bicyclic peptide ligands specific for epha3 | |
| GB201820313D0 (en) | Bicyclic peptide ligands specific for KLK5 | |
| GB201820321D0 (en) | Bicyclic peptide ligands specific for MMP9 | |
| GB201820310D0 (en) | Bicyclic peptide ligands specific for Hsp90 |